NovaVision Participates in Advanced Medical Technology Association’s Annual Event in Washington D.C.
06/20/2007
NOVAVISION VISION RESTORATION THERAPY CHAMPIONS FEATURED IN ANNUAL VALUE OF TECHNOLOGY EVENT ON CAPITOL HILL
Boca Raton, Fla. – June 18, 2007 – NovaVision today announced its participation in the Advanced Medical Technology Association’s (AdvaMed) second annual Value of Technology event on June 20, 2007, on Washington D.C.’s Capitol Hill. The event will feature NovaVision VRTTM Vision Restoration Therapy TM (VRT) and its ability to help restore lost vision to stroke and traumatic brain injury patients with visual field deficits – without the use of drugs or surgery.
AdvaMed invited Dr. Jose G. Romano, M.D., Associate Professor of Neurology, Cerebrovascular Division, at the Miller School of Medicine at the University of Miami, and his patient, Dr. Ramon Moncada, to Washington, D.C., as part of a day in which patients and their medical providers meet with members of the U.S. House of Representatives, Congressional staffers and health organizations to demonstrate the benefits of innovative medical technologies such as NovaVision VRT.
“We are honored that AdvaMed will showcase NovaVision VRT at its event as a premier example of a groundbreaking therapy making a significant difference in people’s lives,” explained Navroze Mehta, President and CEO of NovaVision, who will be in Washington to participate in the event as well as meet with key legislators to discuss the benefits of VRT to stroke and traumatic brain injury survivors. “It’s an opportunity to celebrate the innovative advances in medical technology that improve healthcare and quality of life.”
NovaVision VRT is the first and only FDA-cleared, patented, non-invasive medical device that can enhance vision in people who have been left partially blind due to stroke or brain trauma. Treatment consists of comprehensive diagnostic testing that maps the seeing and non-seeing areas of vision and creates a customized therapy that participants perform daily at home for six to seven months. Patients gradually improve their vision through the repeated detection of a specific pattern of stimulation directed at the border between the seeing and blind areas of the visual field.
Through its proven therapy, NovaVision provides hope to the approximately 1 to 2 million stroke and brain injury survivors in the United States who suffer from major visual field deficits, a number that increases by more than 90,000 each year.
About NovaVision, Inc.
NovaVision, Inc., headquartered in Boca Raton, Fla., develops and provides scientifically based, innovative medical devices and comprehensive solutions to restore the vision of patients with neurological visual impairments. NovaVision’s FDA-cleared NovaVisionVRT™ (VRT) is based on neuroplasticity – the brain’s ability to adapt and form new connections to compensate for injury. NovaVision diagnostic testing maps areas where vision may be improved, and therapy targets and stimulates regions within the brain’s vision-processing areas.
VRT is based on more than 10 years of research with clinical studies published in leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience. Data from a recent retrospective study identified that more than 70 percent of U.S. patients who underwent NovaVision VRT for an initial six-month treatment period showed significant improvement in their vision.
More than 1,000 stroke and traumatic brain injury patients have been treated with NovaVision VRT and clinical results are positive. NovaVision VRT is currently offered at 50 leading neurological, eye and rehabilitation centers nationwide. For more information and a list of centers offering NovaVision VRT, please visit www.novavision.com or call 888.205.0800.